627 related articles for article (PubMed ID: 9454661)
1. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
2. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
Acta Oncol; 1995; 34(6):797-802. PubMed ID: 7576748
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.
Malmström H; Schmidt H; Persson PG; Carstensen J; Nordenskjöld B; Simonsen E
Gynecol Oncol; 1992 Feb; 44(2):172-7. PubMed ID: 1544595
[TBL] [Abstract][Full Text] [Related]
5. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
6. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors.
Chou FF; Eng HL; Sheen-Chen SM
Surgery; 1996 Feb; 119(2):171-7. PubMed ID: 8571202
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
[TBL] [Abstract][Full Text] [Related]
8. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases.
Blom R; Malmström H; Guerrieri C
Int J Gynecol Cancer; 1999 Mar; 9(2):98-104. PubMed ID: 11240749
[TBL] [Abstract][Full Text] [Related]
9. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.
Layfield LJ; Liu K; Dodge R; Barsky SH
Arch Pathol Lab Med; 2000 Feb; 124(2):221-7. PubMed ID: 10656730
[TBL] [Abstract][Full Text] [Related]
10. p53 protein overexpression in smooth muscle tumors of the uterus.
Niemann TH; Raab SS; Lenel JC; Rodgers JR; Robinson RA
Hum Pathol; 1995 Apr; 26(4):375-9. PubMed ID: 7705814
[TBL] [Abstract][Full Text] [Related]
11. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
[TBL] [Abstract][Full Text] [Related]
12. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of p53 protein in uterine sarcomas.
Nordal RR; Kristensen GB; Stenwig AE; Tropé CG; Nesland JM
Gynecol Oncol; 1998 Jul; 70(1):45-8. PubMed ID: 9698472
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer.
Salud A; Porcel JM; Raikundalia B; Camplejohn RS; Taub NA
J Surg Oncol; 1999 Nov; 72(3):167-74. PubMed ID: 10562364
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient.
Haffty BG; Toth M; Flynn S; Fischer D; Carter D
J Clin Oncol; 1992 Dec; 10(12):1839-47. PubMed ID: 1453198
[TBL] [Abstract][Full Text] [Related]
17. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
[TBL] [Abstract][Full Text] [Related]
18. Deoxyribonucleic acid analysis by flow cytometry of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential.
Peters WA; Howard DR; Andersen WA; Figge DC
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 1):1646-53; discussion 1653-4. PubMed ID: 1615971
[TBL] [Abstract][Full Text] [Related]
19. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
